Long-term use of daily subcutaneous low molecular weight heparin in cancer patients with venous thromboembolism: Why hesitate any longer?

Supportive Care in Cancer

Volumn 16, Issue 12, 2008, Pages 1333-1341

  Debourdeau, Philippe ^a   Elalamy, Ismail ^b   De Raignac, Axelle ^c   Meria, Paul ^c   Gornet, Jean Marc ^c   Amah, Yahovi ^d   Korte, Wolfang ^e,f   Marty, Michel ^c   Farge, Dominique ^c  

^a HIA Desgenettes   (France)

^b HÔPITAL TENON   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d University Teaching Hospital   (Togo)

^e Institute for Clinical Chemistry and Hematology   (Switzerland)

^f UNIVERSITY OF BERN   (Switzerland)

Author keywords

Cancer; Low molecular weight heparins; Quality of life; Survival; Venous thromboembolism

Indexed keywords

ANTIVITAMIN K; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO; TINZAPARIN; WARFARIN;

BLEEDING; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERANCE; FRACTURE; HEMATOMA; HEPARIN INDUCED THROMBOCYTOPENIA; HEPARINIZATION; HIGH RISK PATIENT; HUMAN; INJECTION PAIN; INJECTION SITE BLEEDING; INJECTION SITE CONTUSION; INJECTION SITE PAIN; LONG TERM CARE; MONOTHERAPY; OSTEOPOROSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RECURRENT DISEASE; REVIEW; SKIN HEMATOMA; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOSIS PREVENTION; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INJECTIONS, SUBCUTANEOUS; NEOPLASMS; VENOUS THROMBOEMBOLISM;

EID: 55549118564     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-008-0491-4     Document Type: Review

References (73)

1. G Agnelli G Bolis L Capussotti RM Scarpa F Tonelli E Bonizzoni 2006 A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project Ann Surg 243 1 89 95
2. EA Akl FF van Doormaal M Barba G Kamath SY Kim S Kuipers 2007 Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation Cochrane Database Syst Rev 3 CD006652
3. R Balci Akpinar A Celebioglu 2008 Effect of injection duration on bruising associated with subcutaneous heparin: a quasi-experimental within-subject design Int J Nurs Stuides 45 6 812 817
4. A Alcalay T Wun V Khatri HK Chew D Harvey H Zhou 2006 Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival J Clin Oncol 24 7 1112 1118
5. R Alikhan AT Cohen S Combe MM Samama L Desjardins A Eldor 2004 Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study Arch Intern Med 164 9 963 968
6. M Altinbas HS Coskun O Er M Ozkan B Eser A Unal 2004 A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer J Thromb Haemost 2 8 1266 1271
7. RH Andtbacka G Babiera SE Singletary KK Hunt F Meric-Bernstam BW Feig 2006 Incidence and prevention of venous thromboembolism in patients undergoing breast cancer surgery and treated according to clinical pathways Ann Surg 243 1 96 101
8. JA Baron G Gridley E Weiderpass O Nyren M Linet 1998 Venous thromboembolism and cancer Lancet 351 9109 1077 1080
9. JW Blom CJ Doggen S Osanto FR Rosendaal 2005 Malignancies, prothrombotic mutations, and the risk of venous thrombosis JAMA 293 6 715 722
10. RD Bona AD Hickey DM Wallace 2000 Warfarin is safe as secondary prophylaxis in patients with cancer and a previous episode of venous thrombosis Am J Clin Oncol 23 1 71 73
11. HR Buller G Agnelli RD Hull TM Hyers MH Prins GE Raskob 2004 Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on antithrombotic and thrombolytic therapy Chest 126 Suppl 3 401S 428S
12. KD Calligaro WS Bergen MJ Haut RP Savarese DA DeLaurentis 1991 Thromboembolic complications in patients with advanced cancer: anticoagulation versus Greenfield filter placement Ann Vasc Surg 5 2 186 189
13. A Chan RK Woodruff 1992 Complications and failure of anticoagulation therapy in the treatment of venous thromboembolism in patients with disseminated malignancy Aust N Z J Med 22 2 119 122
14. H Chan 2001 Effects of injection duration on site-pain intensity and bruising associated with subcutaneous heparin J Adv Nurs 35 6 882 892
15. HK Chew T Wun D Harvey H Zhou RH White 2006 Incidence of venous thromboembolism and its effect on survival among patients with common cancers Arch Intern Med 166 4 458 464
16. AT Cohen BL Davidson AS Gallus MR Lassen MH Prins W Tomkowski 2006 Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial BMJ 332 7537 325 329
17. P Debourdeau G Meyer H Sayeg Z Marjanovic L Bastit J Cabane 1996 Classical anticoagulant treatment of venous thromboembolic disease in cancer patients. Apropos of a retrospective study of 71 patients Rev Med Intern 17 3 207 212
18. SR Deitcher CM Kessler G Merli JR Rigas RM Lyons J Fareed 2006 Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period Clin Appl Thromb Hemost 12 4 389 396
19. LR Dolovich JS Ginsberg JD Douketis AM Holbrook G Cheah 2000 A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency Arch Intern Med 160 2 181 188
20. G Dranitsaris M Vincent M Crowther 2006 Dalteparin versus warfarin for the prevention of recurrent venous thromboembolic events in cancer patients: a pharmacoeconomic analysis Pharmacoeconomics 24 6 593 607
21. G Ferretti E Bria D Giannarelli P Carlini A Felici M Mandala 2006 Is recurrent venous thromboembolism after therapy reduced by low-molecular-weight heparin compared with oral anticoagulants? Chest 130 6 1808 1816
22. MK Gould AD Dembitzer RL Doyle TJ Hastie AM Garber 1999 Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials Ann Intern Med 130 10 800 809
23. SA Hadley M Chang K Rogers 1996 Effect of syringe size on bruising following subcutaneous heparin injection Am J Crit Care 5 4 271 276
24. JA Heit 2005 Cancer and venous thromboembolism: scope of the problem Cancer Control 12 Suppl 1 5 10
25. JA Heit MD Silverstein DN Mohr TM Petterson WM O'Fallon LJ Melton 3rd 2000 Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study Arch Intern Med 160 6 809 815
26. RJ Hettiarachchi SM Smorenburg J Ginsberg M Levine MH Prins HR Buller 1999 Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread Thromb Haemost 82 2 947 952
27. RJ Hettiarachchi MH Prins AW Lensing HR Buller 1998 Low molecular weight heparin versus unfractionated heparin in the initial treatment of venous thromboembolism Curr Opin Pulm Med 4 4 220 225
28. RD Hull GF Pineo RF Brant AF Mah N Burke R Dear 2006 Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer Am J Med 119 12 1062 1072
29. BA Hutten MH Prins M Gent J Ginsberg JG Tijssen HR Buller 2000 Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis J Clin Oncol 18 17 3078 3083
30. DM Ihnat JL Mills JD Hughes AT Gentile SS Berman A Westerband 1998 Treatment of patients with venous thromboembolism and malignant disease: should vena cava filter placement be routine? J Vasc Surg 28 5 800 807
31. AK Kakkar MN Levine Z Kadziola NR Lemoine V Low HK Patel 2004 Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS) J Clin Oncol 22 10 1944 1948
32. AA Khorana CW Francis E Culakova NM Kuderer GH Lyman 2007 Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients Cancer 110 10 2339 2346
33. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111:4902-4907
34. CP Klerk SM Smorenburg HM Otten AW Lensing MH Prins F Piovella 2005 The effect of low molecular weight heparin on survival in patients with advanced malignancy J Clin Oncol 23 10 2130 2135
35. NM Kuderer AA Khorana GH Lyman CW Francis 2007 A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications Cancer 110 5 1149 1161
36. N Kuzu H Ucar 2001 The effect of cold on the occurrence of bruising, haematoma and pain at the injection site in subcutaneous low molecular weight heparin Int J Nurs Stud 38 1 51 59
37. A Laupacis D Feeny AS Detsky PX Tugwell 1992 How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations CMAJ 146 4 473 481
38. A Lazo-Langner GD Goss JN Spaans MA Rodger 2007 The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials J Thromb Haemost 4 729 737
39. AY Lee MN Levine RI Baker C Bowden AK Kakkar M Prins 2003 Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer N Engl J Med 349 2 146 153
40. AY Lee FR Rickles JA Julian M Gent RI Baker C Bowden 2005 Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism J Clin Oncol 23 10 2123 2129
41. A Leizorovicz AT Cohen AG Turpie CG Olsson PT Vaitkus SZ Goldhaber 2004 Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients Circulation 110 7 874 879
42. AW Lensing MH Prins BL Davidson J Hirsh 1995 Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis Arch Intern Med 155 6 601 607
43. N Levitan A Dowlati SC Remick HI Tahsildar LD Sivinski R Beyth 1999 Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data Medicine (Baltimore) 78 5 285 291
44. GH Lyman AA Khorana A Falanga D Clarke-Pearson C Flowers M Jahanzeb 2007 American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer J Clin Oncol 25 34 5490 5505
45. M Mandala A Falanga A Piccioli P Prandoni EM Pogliani R Labianca 2006 Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM) Crit Rev Oncol Hematol 59 3 194 204
46. M Marchetti A Pistorio M Barone S Serafini G Barosi 2001 Low-molecular-weight heparin versus warfarin for secondary prophylaxis of venous thromboembolism: a cost-effectiveness analysis Am J Med 111 2 130 139
47. DP Mason MA Quader EH Blackstone J Rajeswaran MM DeCamp SC Murthy 2006 Thromboembolism after pneumonectomy for malignancy: an independent marker of poor outcome J Thorac Cardiovasc Surg 131 3 711 718
48. MA Martino E Borges E Williamson S Siegfried AB Cantor J Lancaster 2006 Pulmonary embolism after major abdominal surgery in gynecologic oncology Obstet Gynecol 107 3 666 671
49. G Meyer D Farge F Sauvaget JL Diehl R Herve J Rouffy 1994 Thromboembolic disease and cancer Presse Med 23 38 1767 1771
50. G Meyer Z Marjanovic J Valcke B Lorcerie Y Gruel P Solal-Celigny 2002 Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study Arch Intern Med 162 15 1729 1735
51. P Mismetti S Quenet M Levine G Merli H Decousus E Derobert 2005 Enoxaparin in the treatment of deep vein thrombosis with or without pulmonary embolism: an individual patient data meta-analysis Chest 128 4 2203 2210
52. SI Noble IG Finlay 2005 Is long-term low-molecular-weight heparin acceptable to palliative care patients in the treatment of cancer related venous thromboembolism? A qualitative study Palliat Med 19 3 197 201
53. SI Noble A Nelson C Turner IG Finlay 2006 Acceptability of low molecular weight heparin thromboprophylaxis for inpatients receiving palliative care: qualitative study BMJ 332 7541 577 580
54. S Noboa D Mottier E Oger 2006 Estimation of a potentially preventable fraction of venous thromboembolism: a community-based prospective study J Thromb Haemost 4 12 2720 2722
55. L Opatrny MN Warner 2004 Risk of thrombosis in patients with malignancy and heparin-induced thrombocytopenia Am J Hematol 76 3 240 244
56. HM Otten J Mathijssen H ten Cate M Soesan M Inghels DJ Richel 2004 Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon Arch Intern Med 164 2 190 194
57. G Palareti C Legnani A Lee C Manotti J Hirsh A D'Angelo 2000 A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy Thromb Haemost 84 5 805 810
58. P Prandoni AW Lensing A Piccioli E Bernardi P Simioni B Girolami 2002 Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis Blood 100 10 3484 3488
59. P Prandoni A Falanga A Piccioli 2007 Cancer, thrombosis and heparin-induced thrombocytopenia Thromb Res 120 Suppl 2 S137 S140
60. DJ Quinlan A McQuillan JW Eikelboom 2004 Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials Ann Intern Med 140 3 175 183
61. E Rocha MA Martinez-Gonzalez R Montes C Panizo 2000 Do the low molecular weight heparins improve efficacy and safety of the treatment of deep venous thrombosis? A meta-analysis Haematologica 85 9 935 942
62. S Ross D Soltes 1995 Heparin and haematoma: does ice make a difference? J Adv Nurs 21 3 434 439
63. MM Samama AT Cohen JY Darmon L Desjardins A Eldor C Janbon 1999 A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group N Engl J Med 341 11 793 800
64. K Sideras PL Schaefer SH Okuno JA Sloan L Kutteh TR Fitch 2006 Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial Mayo Clin Proc 81 6 758 767
65. S Siragusa B Cosmi F Piovella J Hirsh JS Ginsberg 1996 Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis Am J Med 100 3 269 277
66. HT Sorensen L Mellemkjaer JH Olsen JA Baron 2000 Prognosis of cancers associated with venous thromboembolism N Engl J Med 343 25 1846 1850
67. PD Stein A Beemath FA Meyers E Skaf J Sanchez RE Olson 2006 Incidence of venous thromboembolism in patients hospitalized with cancer Am J Med 119 1 60 68
68. Ten Cate-Hoek AJ, Prins MH (2008) Low molecular weight heparins in cancer. Management and prevention of venous thromboembolism in patients with malignancies. Thromb Res (in press) doi: 10.1016/j.thromres.2006.12.026
69. MS Tetsche M Norgaard L Pedersen TL Lash HT Sorensen 2006 Prognosis of ovarian cancer subsequent to venous thromboembolism: a nationwide Danish cohort study BMC Cancer 6 189
70. N Vucic R Ostojic T Svircic 2002 Treatment of deep vein thrombosis with oral anticoagulants in patients with malignancy: prospective cohort study Croat Med J 43 3 296 300
71. TE Warkentin 2004 Heparin-induced thrombocytopenia: diagnosis and management Circulation 110 18 e454 e458
72. NI Weijl MF Rutten AH Zwinderman HJ Keizer MA Nooy FR Rosendaal 2000 Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature J Clin Oncol 18 10 2169 2178
73. A Zaybak L Khorshid 2008 A study on the effect of the duration of subcutaneous heparin injection on bruising and pain J Clin Nurs 17 3 378 385